INmune Bio Inc. submitted an Orphan Drug Designation and Scientific Advice package to the European Medicines Agency.
2 reports, 1 independent
Updated Aug 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
INmune Bio Inc. submitted an Orphan Drug Designation and Scientific Advice package to the European Medicines Agency.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Ascletis Pharma expects to submit its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in early 2029.
- Seeking validation for next-gen pMDIs in Europe.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- AbbVie submitted an application for risankizumab approval to the European Medicines Agency.